Financial Snapshot

Revenue
$755.0K
TTM
Gross Margin
57.99%
TTM
Net Earnings
-$9.326M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
7.48%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$13.39M
Q3 2024
Cash
Q3 2024
P/E
-0.5409
Nov 29, 2024 EST
Free Cash Flow
-$2.689M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021
Revenue $731.5K $8.940K $0.00
YoY Change 8082.21%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021
Revenue $731.5K $8.940K $0.00
Cost Of Revenue $300.0K $4.090K $0.00
Gross Profit $431.5K $4.850K $0.00
Gross Profit Margin 58.99% 54.25%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021
Selling, General & Admin $9.650M $1.996M $17.52K
YoY Change 383.38% 11295.15%
% of Gross Profit 2236.48% 41163.51%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $24.89K $3.860K $0.00
YoY Change 544.82%
% of Gross Profit 5.77% 79.59%
Operating Expenses $9.650M $1.996M $17.52K
YoY Change 383.38% 11295.15%
Operating Profit -$9.219M -$1.992M -$17.52K
YoY Change 362.89% 11267.47%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021
Interest Expense -$6.470K -$180.00
YoY Change 3494.44%
% of Operating Profit
Other Income/Expense, Net $6.470K -$6.473K
YoY Change -199.95%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021
Pretax Income -$9.212M -$1.998M -$17.70K
YoY Change 361.07% 11188.47%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.212M -$1.998M -$17.70K
YoY Change 361.07% 11188.47%
Net Earnings / Revenue -1259.4% -22349.66%
Basic Earnings Per Share -$0.57 -$0.19
Diluted Earnings Per Share -$0.57 -$0.12 $0.00

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021
Cash & Short-Term Investments $739.0K $682.9K $22.55K
YoY Change 8.22% 2928.2%
Cash & Equivalents $739.0K $682.9K $22.55K
Short-Term Investments
Other Short-Term Assets $60.95K $11.75K $0.00
YoY Change 418.72%
Inventory $18.50K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $818.5K $694.6K $22.55K
YoY Change 17.83% 2980.31%
Property, Plant & Equipment $215.4K $291.7K $0.00
YoY Change -26.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $16.94K $16.94K $0.00
YoY Change 0.0%
Total Long-Term Assets $232.3K $308.7K $0.00
YoY Change -24.73%
Total Assets $1.051M $1.003M $22.55K
YoY Change
Accounts Payable $140.8K $33.68K
YoY Change 317.96%
Accrued Expenses $70.31K $59.44K $0.00
YoY Change 18.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $167.5K $39.27K
YoY Change -100.0% 326.43%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $211.1K $260.6K $39.27K
YoY Change -19.0% 563.56%
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $64.96K $128.7K $0.00
YoY Change -49.52%
Total Long-Term Liabilities $64.96K $128.7K $0.00
YoY Change -49.52%
Total Liabilities $276.0K $389.3K $39.27K
YoY Change -29.09% 891.24%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021
Basic Shares Outstanding 16.11M shares 10.80M shares
Diluted Shares Outstanding 16.11M shares 10.80M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $5.0441 Million

About MANGOCEUTICALS, INC.

Mangoceuticals Inc is a US-based company operating in Consumer Staples Distribution & Retail industry. The company is headquartered in Dallas, Texas. The company went IPO on 2023-03-21. Mangoceuticals, Inc. is primarily focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. The firm has developed and is commercially marketing a new brand of erectile dysfunction (ED) products under the brand name Mango and a brand of hair loss products under the brand name Grow. These products are produced at a compounding pharmacy using a proprietary combination of United States Food and Drug Administration (FDA) approved ingredients and are available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. The company is marketing and selling these branded ED and hair loss products exclusively online via its Website at www.MangoRx.com. Its customer platform connects consumers to licensed healthcare professionals through its Website for the provision of care via telehealth. The company also owns a global patent portfolio of oral solution.

Industry: Services-Misc Health & Allied Services, NEC Peers: CLS Holdings USA, Inc. MedAvail Holdings, Inc. NEW RITE AID, LLC Walgreens Boots Alliance, Inc.